Inflammatory Bowel Disease Increases Risk for Later Arrhythmias
MONDAY, Nov. 6, 2023 -- Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later arrhythmias, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2023 Category: Pharmaceuticals Source Type: news
To Fast or to Feast?
These tips will help you enjoy the foods at social events when you have ulcerative colitis and still steer clear of a flare. (Source: WebMD Health)
Source: WebMD Health - October 31, 2023 Category: Consumer Health News Source Type: news
Ulcerative Colitis: Social Relationships and Dating
Friendship can be a good medicine when you have ulcerative colitis. Learn how to keep your social life going when you don’t always feel like going out. (Source: WebMD Health)
Source: WebMD Health - October 31, 2023 Category: Consumer Health News Source Type: news
FDA Approves New Drug for Ulcerative Colitis FDA Approves New Drug for Ulcerative Colitis
Mirikizumab (Omvoh) is the first IL-23 inhibitor to be approved in the United States for the treament of moderately to severely active ulcerative colitis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 27, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news
FDA Approves Mirikizumab for Ulcerative Colitis FDA Approves Mirikizumab for Ulcerative Colitis
Mirikizumab (Omvoh) is the first IL-23 inhibitor to be approved in the United States for the treament of moderately to severely active ulcerative colitis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 27, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news
Novel Drug OK'd for Ulcerative Colitis
(MedPage Today) -- The FDA approved mirikizumab (Omvoh) for the treatment of adults with moderately to severely active ulcerative colitis, manufacturer Eli Lilly announced on Thursday.
The injectable drug selectively binds the p19 subunit of interleukin... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 27, 2023 Category: American Health Source Type: news
CONFIDE Study: Impact of Bowel Urgency on Sexual Activity CONFIDE Study: Impact of Bowel Urgency on Sexual Activity
Watch experts discuss how bowel urgency can impact sexual activity for patients with ulcerative colitis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Eli Lilly wins approval of first-in-class ulcerative colitis drug Omvoh
(Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
FDA Approves Omvoh (mirikizumab-mrkz), a First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 26, 2023 Category: Drugs & Pharmacology Source Type: news
Low Serum Vitamin D Levels Linked to Ulcerative Colitis Low Serum Vitamin D Levels Linked to Ulcerative Colitis
Serum vitamin D levels were lower and the prevalence of vitamin D deficiency was higher in patients with ulcerative colitis compared with controls.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 26, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
CONFIDE Study: Use of Diapers in UC CONFIDE Study: Use of Diapers in UC
What are the most relevant symptoms and the important conversations in ulcerative colitis? Watch experts discuss the impact of bowel urgency and some of the findings from the CONFIDE study.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Controversial Kratom Appeared to Cause Severe Ulcerative Colitis Flare
(MedPage Today) -- VANCOUVER, British Columbia -- In a case believed to be the first such report in medical literature, researchers said here they have documented how use of the controversial substance kratom (Mitragyna speciosa) appeared to... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 24, 2023 Category: American Health Source Type: news
FDA Approves Subcutaneous Infliximab for IBD FDA Approves Subcutaneous Infliximab for IBD
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2023 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Media News - October 23, 2023 Category: Pharmaceuticals Source Type: news
